Amgen Presents Groundbreaking Repatha Phase 3 Trial Results at AHA Scientific Sessions 2025 Amgen's Phase 3 VESALIUS-CV study data shows that Repatha can significantly reduce cardiovascular events, transforming treatment strategies.

Amgen Presents Groundbreaking Repatha Phase 3 Trial Results at AHA Scientific Sessions 2025 #United_States #New_Orleans #Amgen #Repatha #Cardiovascular_Trials